NCT05921266Completed
Urolithin A Supplementation in Middle-aged Adults With Obesity
Urolithin A Supplementation to Improve Endothelial and Cerebrovascular Function in Middle-aged Adults With Obesity
Source: ClinicalTrials.gov · Last updated 26 Jun 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn about the effect of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. The main question it aims to answer is: \- Does urolithin A supplementation improve blood flow in large and small blood vessels in middle-aged adults with obesity? Participants will be asked to: * Take the dietary supplement daily for 4 weeks * Attend two study visits to have their blood vessels checked, answer questionnaires, and give a sample of blood Researchers will compare people who took the dietary supplement with others who took a placebo to see if the blood flow in the blood vessels improved.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 12 Jun 2023
- Start date
- 2 Oct 2023
- Primary completion date
- 14 May 2025
- Lead sponsor
- University of Oklahoma
- Diseases
- Obesity
- NCT number
- NCT05921266
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 2 Oct 2023 to the primary completion date, 14 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of uncontrolled hypertension
- History of uncontrolled type 1 or type 2 diabetes mellitus
- Significant cardiac disease or chest pain in the last 6 months
- History of untreated depression or anxiety
- History of cognitive impairment
- History of uncontrolled significant GI disease (e.g., IBS, Crohn's disease)
- Allergy or intolerance to one or more of the intervention components
- Undergoing treatment for active cancer
- History of neurodegenerative disorders (e.g., multiple sclerosis)
- Presence of any condition affecting swallowing ability
- Any other medical condition that the investigators deem would adversely affect the participant's safety or ability to complete the study
Other
- Pregnant or breastfeeding women, or women who intend to become pregnant within the study period
Who the study is looking for
- Age: 40-64 years old, inclusive
- Obesity \[BMI ≥30 kg/m2\]
- Ability to read, write, and speak English
- Competence to provide written informed consent
Age in the registry: 40 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Translational GeroScience Laboratory - O'Donoghue Research Building Coordinator of this site? Confirm its status | Oklahoma City | United States | Unknown status |
Related publications
- Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity: A Randomized Clinical Trial.JAMA Netw Open · 2026 · PMID 42853569
This page is information, not medical advice. Discuss any trial with your doctor.